Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Mollie Wolfe

Physician Assistant Jacksonville, FL Physician Assistant

NPI 1598454712 CMS profile 11521446

8823 San Jose Blvd, Jacksonville, FL 32217

Open in the dashboard

General payments

$9,941

467 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mollie Wolfe of Jacksonville, FL is reported in the CMS Open Payments database as having received $9,941 across 467 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,968 188
2024 General $3,486 158
2023 General $2,487 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mollie Wolfe
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mollie Wolfe were reported at $3,968. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mollie Wolfe Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $2,487 $167 $52–$557 $160
2024 $3,486 $178 $55–$600 $164
2025 $3,968 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,738 98 payments
  2. Lundbeck LLC $973 58 payments
  3. Novartis Pharmaceuticals Corporation $642 30 payments
  4. Jazz Pharmaceuticals Inc. $599 20 payments
  5. Otsuka America Pharmaceutical, Inc. $501 24 payments
  6. Argenx US, Inc. $481 14 payments
  7. Teva Pharmaceuticals USA, Inc. $429 22 payments
  8. UCB, Inc. $424 16 payments
  9. EMD Serono, Inc. $364 23 payments
  10. Pfizer Inc. $361 20 payments
  11. Other $3,430 142 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $9,697 464 payments
  2. Education $244 3 payments
Products named General payments · program years 2023–2025
  1. QULIPTA $1,065 72 payments
  2. UBRELVY $984 67 payments
  3. VYEPTI $924 55 payments
  4. KESIMPTA $642 30 payments
  5. XYWAV $551 17 payments
  6. BOTOX $492 20 payments
  7. REXULTI $339 13 payments
  8. ZAVZPRET $322 18 payments
  9. Leqembi $321 9 payments
  10. NURTEC ODT $298 17 payments
  11. Other $4,893 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

319

Median for Physician Assistant: 241

Drug cost

$29,412

Median for Physician Assistant: $4,110

Branded share of claims

9.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 14 $19,496
Rivastigmine Generic 15 $2,098
Dimethyl Fumarate Generic 11 $1,760
Memantine Hcl Generic 54 $1,649
Gabapentin Generic 35 $945
Oxcarbazepine Generic 11 $705
Levetiracetam Generic 18 $494
Duloxetine Hcl Generic 22 $386
Donepezil Hcl Generic 31 $342
Pyridostigmine Bromide Generic 12 $309

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$338 — —
VYEPTI
$318 — —
KESIMPTA
$271 — —
Leqembi
$247 — —
UBRELVY
$231 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

467 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record